Abstract:The objective of this research was to evaluate the correlation between inhibitory zones and MIC when testing ceftazidime-avibactam using disk diffusion, Etest, and broth microdilution method established by the Clinical and Laboratory Standards Institute (CLSI). Four-hundred and 58 isolates of Enterobacterales isolated from 54 medical centers from the China Antimicrobial Surveillance Network (CHINET) in 2016 to 2020 were collected. Antimicrobial susceptibility testing using broth microdilution, Etest, and disk diffusion were performed according to the CLSI. Of the 458 Enterobacterales, 17.2% (79/458) and 82.8%(379/458) were resistant or susceptible to ceftazidime-avibactam by broth microdilution, respectively. Compared with the broth microdilution method, the categorical agreement (CA) and essential agreement (EA) of the Etest were 99.6% (456/458) and 94.8% (434/458), respectively; the major error (ME) and very major error (VME) were both 0.2% (1/458). For disk diffusion, the CA and VME were 99.8% (457/458) and 0.2% (1/458), respectively. For Escherichia coli, the CA and EA of the Etest were 100% and 97.1% (135/139), respectively. The CA of the disk diffusion was 100%. For Klebsiella pneumoniae, the CA and EA of the Etest were 99.3% (288/290) and 93.4% (271/290), respectively, the ME and VME were both 0.3% (1/290). The CA and VME of disk diffusion were 99.7% (289/290) and 0.3% (1/290), respectively. For other Enterobacterales, the CA and EA of the Etest were 100% and 96.6% (28/29), respectively. The CA of the disk diffusion was 100%. Ceftazidime-avibactam disk diffusion (30/20-μg disks) and Etest demonstrated good performance for ceftazidime-avibactam susceptibility testing against Enterobacterales clinical isolates. IMPORTANCE Multidrug-resistant Gram-negative bacteria, especially for extended-spectrum β-lactamases-producing and carbapenemase-producing Enterobacterales, are disseminating rapidly around the world. Treatment options for these infections are limited, which prompt the development of novel or combinational therapies to combat the infections caused by multidrug-resistant pathogens. The newly available β-lactam combination agent ceftazidime-avibactam has been demonstrated good in vitro and in vivo activity against ESBL, AmpC, KPC-2, or OXA-48-like-producing isolates and has shown promise in treating carbapenem-resistant Enterobacterales infections. Concerningly, there are few available automated systems for ceftazidime-avibactam susceptibility testing, and the broth microdilution method is hard to perform in most routine laboratories. Therefore, we urgently need an economical and practical method for the accurate detection of ceftazidime-avibactam activity against Gram-negative bacilli. Here, we evaluate the performance of the disk diffusion and Etest compared with the reference broth microdilution method against Enterobacterales clinical strains.

Study on minimum inhibitory concentrations and its influence factors of cefathiamidine

A multicenter study on the in vitro antibacterial activity of cefoselis against common clinical bacteria

A 10 Year Surveillance for Antimicrobial Susceptibility of Escherichia Coli and Klebsiella Pneumoniae in Community- and Hospital-Associated Intra-Abdominal Infections in China

Antimicrobial susceptibilities of aerobic and facultative gram-negative bacilli isolated from Chinese patients with urinary tract infections between 2010 and 2014

Evaluation of different tigecycline susceptibility testing methods for Acinetobacter baumannii

Analysis of Antimicrobial Resistance of 266 Escherichia Coli

In vivo antibacterial effect of cefathiamidine against mouse septicemia

Study on the in vitro antibacterial activities of the antibacterial drugs against methicillin resistant coagulase-negative staphylococci

In vitro activity of cefcapene

Study on the in vitro antibacterial activity of cefathiamidine and other five antimicrobial agents against Gram-positive cocci

In vitro activity of cefazolin pentahydrate

In vitro activity of cefditoren and other comparators against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis causing community-acquired respiratory tract infections in China.

Antibacterial Activity of Cefepime on the Clinically Common Pathogenic Bacteria:Survey of 576 Strains

In Vitro Activities of Ceftaroline/Avibactam, Ceftazidime/Avibactam, and Other Comparators Against Pathogens from Various Complicated Infections in China.

In Vitro Antibacterial Activity of Cefminox

Assessment of Ceftazidime-Avibactam 30/20-Μg Disk, Etest Versus Broth Microdilution Results when Tested Against Enterobacterales Clinical Isolates

In Vitro Antibacterial Activity of Fusidic Acid

In vitro activities of cefoselis compared to β-lactams and other antibacterial agents aganst gram-positive and gram-negative clinical isolates

The influencing factors and methodological evaluation on tigecycline susceptibility testing methods for Acinetobacter baumannii and Klebsiella pneumoniae

Evaluation of Etests and the disk diffusion method for assessment of the activity of ceftazidime-avibactam against Enterobacterales and Pseudomonas aeruginosa in China

Analysis of cefoxitin-sensitive, penicillin-resistant Staphylococcus tested by disk diffusion method